Dr. Danny Fishelovitch has more than 10 years of experience in the pharmaceutical industry. He leads the Chemistry, Manufacturing and Controls (CMC) at Mitoconix Bio. Previously, he worked for approximately 4 years at Neuroderm Ltd. that was acquired by Mitsubishi Tanabe Pharma where he served at various positions such as Head of CMC, CMC manager and project manager. Prior to that, Danny was a CMC leader and a formulator researcher at Teva pharmaceuticals Ltd. Innovative R&D.
Danny specializes in the development of various sterile and solid dosage forms as well as drug device combination. In addition, Danny has extensive experience in the scale-up and optimization of manufacturing processes by applying Quality-by-Design methodology.
Danny is a pharmacist and computer scientist by training and holds a Ph.D. in Structural Bioinformatics from the Tel-Aviv University. He is an author of eight published scientific papers.